Onco Actu du 4 décembre 2018

	1.4 Biologie - Technos
WHO looks at standards in "uncharted water" of gene editing [Reuters] The World Health Organization (WHO) warned on Monday that gene editing may have "unintended consequences" and said it was establishing a team of experts to set clear guidelines and standards after studying ethical and safety issues.
The CRISPR Baby Scandal Gets Worse by the Day [The Atlantic] The edited cells don’t seem to have been edited in the right way. He planned to delete a small section of the CCR5 gene, mimicking a naturally occurring mutation called delta 32 that’s found in about 10 percent of Europeans. But according to Sean Ryder, a biochemist from the University of Massachusetts Medical School, He’s slides show no sign of delta 32 in either girl.
	2.5 Etiologie - Gènes
Large-scale genomic study discovers 40 new genetic variants associated with colorectal cancer risk [Fred Hutch] Collaboration involved researchers from more than 130 institutions globally.
	3. Prévention
Tailored Lifestyle Feedback Given During Colorectal Cancer Screening Improved Patients’ Health Behaviors [AACR] Ultimately, 1,054 enrolled in the study. Participants were asked to complete two lifestyle questionnaires, one before screening and one a year after screening. The lifestyle questionnaires included questions on smoking status, weight, physical activity, alcohol consumption, and intake of fruits, vegetables, and red or processed meat.
	5.1 Traitements - Pré-clinique
New drug combination could be more effective against melanoma [MIT News] A new study from MIT suggests that combining kinase inhibitors with experimental drugs known as ribonucleases could lead to better results. In tests with human cancer cells, the researchers found that the two drugs given together kill cells much more effectively than either drug does on its own.
	5.12 Immunothérapies
How Can We Turn “Cold” Pancreatic Tumors “Hot”? [Cancer Research Catalyst] “We’ve been testing the hypothesis that a naturally nonimmunogenic cancer, like pancreatic cancer, requires at least two steps in order to induce an optimal immune response,” said Jaffee. “The first step is to activate a good T cell.”
	5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
There Is a Magic Bullet for Some Cancers. What If It Misses? [Bloomberg] CAR-T therapies were heralded as one-time cures for some dire cases. Many patients, it turns out, relapse over time after a complete remission.
	5.2.1 Pharma - Partenariats
J&J shells out $500M to sew up Argenyx's blood cancer hopeful cusatuzumab [FierceBiotech] The drug is already in a phase 1/2 combo test with Celgene blood cancer drug Vidaza for newly diagnosed, elderly patients with acute myeloid leukemia (AML) and high-risk MDS who are unfit for chemotherapy.
J&J pays $500M in cash to grab rights to a new star cancer drug at argenx [EndPoints] J&J execs believe they have found their next big cancer drug. Early Monday the pharma giant announced that it was paying Belgium’s argenx $500 million — $300 million as an upfront and $200 million for equity — to grab the worldwide commercial rights to cusatuzumab (ARGX-110) to treat acute myeloid leukemia and high-risk myelodysplastic syndromes.
	5.3 Traitements - FDA, EMA, NICE...
Red tape preventing cancer patients from accessing new drugs [The Guardian] The report finds that recent years have seen a boom in new drugs for blood cancers and lung cancer, but some other cancers have had no new drugs licensed since 2000.
Despite innovation, Europeans wait years for new cancer drugs [Reuters] It also found big differences in rates of development of new cancer drugs for various types of the disease: 15 drugs for breast cancer were licensed in Europe from 2000 to 2016, but none at all for brain tumours.
New cancer drugs taking longer to reach NHS patients [Institute of Cancer Research] The report, From patent to patient – analysing access to innovative cancer drugs, examines all 97 cancer drugs licensed for 177 indications through the European Medicines Agency between 2000 and 2016, to assess how successful the system is being at delivering new treatments for patients.
	5.4 Traitements - Economie
‘A loss for the rest of us’: An FDA approval is a boon for a drug maker, but could come at a major cost for patients [STAT] “The big problem is, this is not what the Orphan Drug Act was designed to do,” Burns said. “It was designed to incentivize innovation. That’s not what’s happening here, because there’s no biopharmaceutical innovation.”
	6.2 Implants mammaires
Breast implants and anaplastic large cell lymphoma [BMJ] Textured breast prostheses will continue to be offered to women who need anatomically shaped prostheses. The current strategy is to discuss the risk of ALCL without causing unnecessary anxiety. Absolute risks remain low. No professional body or regulator has recommended that textured implants need to be removed prophylactically.